Beta Blocker & Calcium Channel Blocker Toxicity Treatment

Added:

High-Dose Insulin Euglycemia and Lipid Emulsion as Primary Therapies

While traditional guidelines emphasize atropine, calcium, and glucagon for treating beta-blocker and calcium channel blocker toxicity, contemporary toxicology increasingly challenges this hierarchy. Critics argue that traditional therapies are frequently ineffective in severe overdoses, and that glucagon is associated with high failure rates, high costs, and severe vomiting. Instead, modern experts advocate for the early initiation of High-Dose Insulin Euglycemia (HDI) and Intravenous Lipid Emulsion (ILE) therapy. HDI acts as a potent inotrope by overcoming the metabolic starvation of myocardial cells, while ILE sequesters lipophilic drugs from receptor sites. This perspective shifts the paradigm from sequential symptomatic drug administration to early, aggressive metabolic resuscitation.

Understanding of cardiovascular physiology, specifically the cardiac conduction system and excitation-contraction coupling in myocardial cells.
Fundamental knowledge of autonomic nervous system pharmacology, focusing on beta-adrenergic receptor sub-types (beta-1, beta-2) and their physiological effects.
Basic mechanism of action of calcium channel blockers (dihydropyridines vs. non-dihydropyridines) and their therapeutic indications.
Familiarity with the clinical presentations of bradycardia, hypotension, and cardiogenic shock.
In-depth study of High-Dose Insulin Euglycemia Therapy (HIET) and Intravenous Lipid Emulsion (ILE) therapy for severe, refractory cardiotoxicity.
Differential diagnosis of drug-induced bradycardia and shock, including distinguishing between beta-blocker, calcium channel blocker, and digoxin toxicities.
Clinical application of mechanical circulatory support, such as transvenous cardiac pacing and Extracorporeal Membrane Oxygenation (ECMO) in toxicological emergencies.
Management of metabolic complications arising from overdose treatments, such as severe hypokalemia, hypoglycemia, and fluid overload.
8.9K views128likes3:43@MedMasteryOriginal Release: 2022-07-25

Beta blocker and calcium channel blocker toxicity causes bradycardia and hypotension by blocking calcium influx into cardiac myocytes; treatment follows the ABC roadmap with intravenous calcium salts (directly increasing calcium availability) and glucagon (indirectly activating calcium channels through beta-receptor stimulation), supported by atropine for heart rate, epinephrine for systemic support, and hyperinsulinemia-euglycemia for metabolic support, with magnesium added specifically for sotalol toxicity.